Scholars Central

Conference abstractPublished 6 Nov 2017

MAP4K3/GLK is a novel therapeutic target for IL-17A-mediated autoimmune disease

Authors: Tse-Hua Tan

National Health Research Institutes, Taiwan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

T-cell receptor signaling activates the kinase MAP4K3 (also named GLK) by inducing its direct interaction with the upstream adaptor protein SLP-76. Activated GLK directly phosphorylates and activates PKC-Ã?¸, which is required for NF-Ã?ºB activation in T cells. Moreover, GLK-deficient mice show impaired Th17 differentiation and are resistant to IL-17Amediated experimental autoimmune encephalomyelitis (EAE). Consistently, autoimmune SLE and rheumatoid arthritis (RA) patients show significantly increased GLK levels in T cells; the percentage of GLK-overexpressing T cells is correlated with autoimmune disease severity. Recently, we generated and characterized T-cell specific GLK transgenic (Lck-GLK Tg) mice and found that these transgenic mice spontaneously develop autoimmune diseases with an induction of systemic inflammation and an increase of autoantibodies (ANA, anti-dsDNA, rheumatoid factor). We found that GLK signaling specifically induced IL-17A transcription in the T cells of GLK transgenic mice. Moreover, the induction of serum IL-17A and autoantibodies in Lck-GLK Tg mice was abolished by treatment of a GLK inhibitor. The disease severity and serum IL-17A levels in EAE or collagen-induced arthritis mouse models were also attenuated by the GLK inhibitor treatment. In addition, GLK protein levels were also overexpressed in tumor tissues of lung cancer or hepatoma patients. The GLK overexpression was correlated with increased recurrence risks and poor recurrence-free survival rates of lung cancer and hepatoma. Collectively, MAP4K3/GLK is a novel diagnostic/prognostic biomarker and therapeutic target for cancer and IL-17A-mediated autoimmune diseases.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Cellular Immunology
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Tse-Hua Tan”